Domainex opens new Biology Centre of Excellence in Cambridge, UK
February 14, 2024Business Services Pharmacy, domainex, facility
Domainex has announced that it has opened a new Biology Centre of Excellence at the Unity Campus at Pampisford, Cambridge, …
FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment
February 14, 2024Medical Communications FDA, Oncology, Onivyde, ipsen, pancreatic adenocarcinoma
Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for …
EC approves Vertex’s Casgevy for sickle cell disease treatment
February 13, 2024Medical Communications Casgevy, European Commission, Haematology, Vertex pharmaceuticals, sickle cell disease
Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a CRISPR/Cas9 …
DelSiTech and Tolmar announce global license and development agreement
February 13, 2024Medical Communications DelSiTech, Pharmacy, Tolmar, collaboration
DelSiTech and Tolmar International have announced that they have entered into a global license and development agreement, following a previous …
J&J’s nipocalimab gains breakthrough therapy designation from FDA for HDFN treatment
February 12, 2024Medical Communications Breakthrough Therapy Designation, FDA, HDFN, J&J, Reproductive health
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) …
GSK gains FDA Fast Track designation for chronic hepatitis B treatment
February 12, 2024Medical Communications FDA, GSK, Hepatology, fast track designation, hepatitis B
GSK has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational …
BioNTech and Autolus announce CAR T-cell therapy collaboration
February 9, 2024Research and Development Autolus, BioNTech, CAR T-cell, Oncology, collaboration
BioNTech and Autolus Therapeutics have announced that they have entered a strategic collaboration intended to further both companies’ autologous CAR …
Fresenius Medical Care gains FDA 501(k) clearance for haemodialysis system
February 9, 2024Medical Communications 501(k), FDA, Fresenius Medical Care, Nephrology, dialysis
Fresenius Medical Care has announced that it has received US Food and Drug Administration (FDA) 501(k) clearance for its 5008X …
Regenxbio announces positive data from trial for MPS II treatment
February 8, 2024Research and Development Hunter syndrome, MPS II, Neurology, Regenxbio, clinical trial
Regenxbio has announced topline results from the phase 1/2/3 CAMPSIITE trial of RGX-121 for the treatment of patients up to …
Tenax Therapeutics enrolls first patient in phase 3 trial for pulmonary hypertension treatment
February 8, 2024Research and Development Cardiology, Tenax Therapeutics, clinical trial, pulmonary hypertension
Tenax Therapeutics has announced that it has enrolled the first patient in its phase 3 LEVEL study, which aims to …
Jazz Pharmaceuticals enters agreement to acquire rights to KRAS inhibitor programme from Redx Pharma
February 7, 2024Business Services Pharmacy, RedX Pharma, acquisition, jazz pharmaceuticals
Jazz Pharmaceuticals and Redx Pharma have announced that the companies have signed a definitive agreement under which Jazz will acquire …
Medidata and Sanofi Vaccines extend collaboration
February 7, 2024Research and Development Immunology, Medidata, Sanofi Vaccines, eCOA
Medidata and Sanofi Vaccines have announced a collaboration utilising Medidata electronic clinical outcome assessment (eCOA) within vaccine trials, building on …
Novartis to acquire MorphoSys AG for €2.7bn
February 6, 2024Business Services Novartis, Pharmacy, acquisition, morphosys
Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, or €68 per share. The …
Vertex announces positive results from trial for cystic fibrosis combination treatment
February 6, 2024Research and Development Chronic Diseases, Vertex pharmaceuticals, clinical trial, combination treatment, cystic fibrosis
Vertex Pharmaceuticals has announced positive results from its once-daily vanzacaftor/tezacaftor/deutivacaftor programme, the company’s phase 3 programme for the treatment of …
Zuellig Pharma acquires Cialis and Alimta from Eli Lilly in certain ASEAN markets
February 5, 2024Business Services Cialis, Eli Lilly, Pharmacy, Zuellig Pharma, acquisition
Zuellig Pharma has announced that it has completed the acquisition of two brands Cialis (Tadalafil) and Alita (Pemetrexed) from Eli …
Regeneron’s linvoseltamab gains EMA filing acceptance for R/R MM treatment
February 5, 2024Medical Communications EMA, Oncology, Regeneron, linvoseltamab, multiple myeloma
Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorisation Application (MAA) for …
Vivet Therapeutics gains €4.9m for gene therapy development
February 2, 2024Research and Development CTX, Neurology, Vivet Therapeutics, funding, gene therapy
Vivet Therapeutics has announced that it has received €4.9m financing from the French Government for the advanced development of a …
AstraZeneca shares results from phase 3 trial of acoramidis in adults with ATTR-CM
February 2, 2024Research and Development ATTR-CM, AstraZeneca, Cardiology, acoramidis, clinical trial
AstraZeneca has announced positive high-level results from the phase 3 trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) …
NICE recommends SC treatment of AbbVie’s Tepkinly for patients with DLBCL
February 1, 2024Medical Communications AbbVie, DLBCL, NICE, Oncology, lymphoma
AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended Tepkinly (epcoritamab) as a treatment …
FDA grants ODD to Revolo Biotherapeutics’ eosinophilic esophagitis treatment
February 1, 2024Medical Communications FDA, ODD, Pharmacy, Revolo Biotherapeutics, eosinophilic esophagitis
Revolo Biotherapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ‘1104, …
Latest content
FibroFind appoints Lee Borthwick as CEO
